Dr. McDermott on Lessons From the IMmotion150 Trial in RCC

David F. McDermott, MD
Published: Wednesday, Mar 08, 2017



David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

As the first large-scale look at atezolizumab in this setting, IMmotion150 will impact how immune agents are used in the first and second line, says McDermott.

In addition to aiding in design for a phase III trial, the results of IMmotion150 suggest that atezolizumab may be effective in the adjuvant setting.
 


David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

As the first large-scale look at atezolizumab in this setting, IMmotion150 will impact how immune agents are used in the first and second line, says McDermott.

In addition to aiding in design for a phase III trial, the results of IMmotion150 suggest that atezolizumab may be effective in the adjuvant setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x